Holen Sie sich die Stockscreener-App
11.08
1.65%
0.18
Schlusskurs vom Vortag:
$10.90
Offen:
$10.94
24-Stunden-Volumen:
663.19K
Relative Volume:
0.42
Marktkapitalisierung:
$784.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.81M
KGV:
-22.17
EPS:
-0.4998
Netto-Cashflow:
$-122.54M
1W Leistung:
+12.95%
1M Leistung:
-3.99%
6M Leistung:
+140.35%
1J Leistung:
+56.94%
1-Tages-Spanne:
$10.70
$11.27
1-Wochen-Bereich:
$9.99
$13.00
52-Wochen-Spanne:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.07 | 772.82M | 0 | -4.81M | -122.54M | -0.4998 |
VRTX
Vertex Pharmaceuticals Inc
|
435.20 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
759.39 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.94 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.34 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Omeros Achieves Profitability as Strategic Moves Slash Debt - AD HOC NEWS
Breakout Zone: Is Omeros Corporation impacted by rising rates2026 Summary & Safe Entry Point Identification - baoquankhu1.vn
Omeros (NASDAQ:OMER) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Omeros Turns Corner With Novo Deal, YARTEMLEA Launch - TipRanks
Omeros Q4 2025 earnings preview - MSN
HC Wainwright Brokers Increase Earnings Estimates for Omeros - MarketBeat
Omeros rises as Novo deal boosts Q4 earnings - MSN
Travel Stocks: Can Omeros Corporation withstand a market correctionMarket Volume Report & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Omeros (NASDAQ:OMER) Shares Down 6.5%Here's Why - MarketBeat
Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates (OMER) - Seeking Alpha
Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript - Insider Monkey
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
Omeros Shares Surge on Stellar Earnings and Strategic Progress - AD HOC NEWS
Omeros stock rises after Q4 earnings beat (OMER:NASDAQ) - Seeking Alpha
Omeros Sees Unusually Large Options Volume (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
Omeros Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027 - MSN
Omeros reports Q4 EPS $1.22, consensus 36c - TipRanks
Transcript : Omeros Corporation, Q4 2025 Earnings Call, Mar 31, 2026 - marketscreener.com
Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaroun - GuruFocus
Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $3.69 EPS - MarketBeat
OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN
Omeros Corp reports results for the quarter ended September 30Earnings Summary - TradingView
Omeros Corporation Reports Q4 and Full-Year 2025 Results - National Today
Omeros Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Omeros Corporation Q4 2025 sees remarkable earnings beat By Investing.com - Investing.com South Africa
Earnings call transcript: Omeros Corporation Q4 2025 sees remarkable earnings beat - Investing.com
Omeros (OMER) Posts Strong Q4 Results Amid Strategic Advances - GuruFocus
OMEROS ($OMER) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Omeros: Q4 Earnings Snapshot - marketscreener.com
Omeros (NASDAQ: OMER) wins TA‑TMA approval and $240M Novo Nordisk pact - Stock Titan
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results - The Joplin Globe
BRIEF-Omeros Corporation Q4 EPS USD 1.22 - TradingView
After $240M Novo deal, Omeros launches first approved TA-TMA drug - Stock Titan
Omeros Corporation's Cash Flow Timelines and Formulary Approval Claims Clash in 2025 Earnings Call - Bitget
Omeros Q4 2025 Earnings Call Transcript - MarketBeat
Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Aug Sectors: Is Omeros Corporation a play on infrastructure spendingFed Meeting & Reliable Volume Spike Alerts - baoquankhu1.vn
Vanguard entities disaggregate OMER holdings (OMER) after internal realignment - Stock Titan
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 - BioSpace
Omeros Corp Stock: Biotech Innovator Focused on Complement Inhibitors Ahead of Q4 2025 Earnings - AD HOC NEWS
Omeros Corporation (OMER.US) is scheduled to release its earnings report after the market closes on March 31. - 富途牛牛
Sentiment Recap: Can Omeros Corporation withstand a market correctionQuarterly Profit Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Omeros (OMER) Projected to Post Earnings on Monday - MarketBeat
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - PharmiWeb.com
GeekWire Awards: Billion-dollar deals, rare IPO, pharma pact, and mega-round vie for Deal of the Year - GeekWire
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
Omeros Corporation-Aktie (OMER) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Option Exercise |
3.06 |
30,000 |
91,800 |
30,000 |
| Borges David J. | VP, Finance & CAO |
Jan 12 '26 |
Sale |
12.72 |
30,000 |
381,600 |
0 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Sale |
12.31 |
30,000 |
369,315 |
0 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):